Shingles and Dementia Risk: What the Latest Research Reveals

For years, chickenpox was considered a childhood illness with lasting immunity. However, the virus responsible, varicella-zoster, remains dormant in the nervous system and can reactivate decades later as herpes zoster, or shingles. Emerging research now suggests a potential link between shingles reactivation and an increased risk of dementia, while as well indicating that vaccination against shingles may offer a protective effect.

The Link Between Shingles and Dementia

A large-scale study published in Nature Medicine analyzed the health records of over 100 million people in the United States between 2007 and 2023. Researchers, after controlling for nearly 400 variables including demographics, socioeconomic factors, and comorbidities, found a consistent association between varicella-zoster virus (VZV) reactivation and dementia . Individuals who had received the shingles vaccine were found to be 27% to 33% less likely to develop dementia within three years of immunization .

Understanding Varicella-Zoster Virus Reactivation

Varicella-zoster virus causes chickenpox in childhood and then establishes lifelong latency in the nervous system. Reactivation typically occurs after age 50, manifesting as shingles – characterized by burning pain, tingling, and a rash with fluid-filled blisters, usually on one side of the body . While many reactivations are controlled by the immune system without noticeable symptoms, others result in a full shingles outbreak.

The study revealed that individuals experiencing multiple shingles episodes faced a higher dementia risk compared to those with a single outbreak, with the risk increasing by 7% to 9% between three and nine years after the second episode . This reinforces the idea that repeated viral activity could have long-term effects on brain health.

How Might Shingles Affect the Brain?

Dementia is a complex condition with multiple contributing factors. Recent research suggests viral infections may play a role in triggering or accelerating neurodegenerative processes. However, the precise mechanisms by which VZV reactivation could influence cognitive decline are still being investigated .

Several hypotheses are being explored:

• Direct Viral Impact: The virus may directly affect brain regions involved in memory and cognitive function.
• Inflammation: The body’s immune response to the virus causes inflammation, which, when repeated over time, could be toxic to brain tissue.
• Treatment Effects: The role of pain management treatments for shingles is also being investigated, though no definitive conclusions have been reached.

The Protective Role of Vaccination

Shingles vaccines are recommended for adults over 50 and individuals with compromised immune systems. Two main types are available: an older vaccine using weakened live viruses and a newer vaccine utilizing inactive virus fragments .

The Nature Medicine study compared both vaccination strategies and found that those receiving two doses of the more modern vaccine experienced better outcomes. This group showed an 18% lower risk of dementia five years post-vaccination compared to those receiving a single dose of the older vaccine .

The data also indicated particularly significant benefits for older women. Among women over 50 who received the traditional vaccine, a 35% reduction in dementia risk was observed at three years. In women aged 80-89 who received two doses of the newer vaccine, the reduction reached 39% .

Looking Ahead

While these findings do not establish the shingles vaccine as a definitive dementia prevention strategy, they provide valuable evidence in a field where preventative measures are limited . Further research is needed to fully understand the complex relationship between VZV reactivation, inflammation, and cognitive decline, and to explore whether antiviral treatments could also offer neuroprotective benefits . A systematic review and meta-analysis also reported a decreased risk of dementia with herpes zoster vaccination .

Recent studies also suggest that the RSV vaccine (Arexyv) may also be associated with a reduced risk of dementia compared to the annual flu vaccine .